Michael Pulsipher, MD
Tisagenlecleucel (Kymriah), the first FDA-approved CAR T-cell therapy, induced a complete remission (CR) with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma (ALL).
Patient quality of life improved from baseline to 3 months by 2 different assessment instruments.
Pulsipher M, Buechner J, Grupp SA, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis. Presented at 2017 SOHO Annual Meeting. Abstract ALL-152.
... to read the full story